IDEXX Laboratories, Inc. $IDXX Shares Acquired by Laurel Wealth Advisors LLC

Laurel Wealth Advisors LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 53,536.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 11,800 shares of the company’s stock after buying an additional 11,778 shares during the period. Laurel Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $6,329,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. STF Management LP lifted its stake in shares of IDEXX Laboratories by 1.3% during the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after purchasing an additional 16 shares during the period. Clearstead Trust LLC increased its stake in IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after purchasing an additional 16 shares during the last quarter. Stratos Wealth Partners LTD. lifted its position in IDEXX Laboratories by 1.7% during the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after buying an additional 18 shares during the period. Red Spruce Capital LLC boosted its stake in IDEXX Laboratories by 1.1% in the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after buying an additional 19 shares during the last quarter. Finally, Huntington National Bank grew its holdings in IDEXX Laboratories by 0.5% in the 2nd quarter. Huntington National Bank now owns 3,651 shares of the company’s stock valued at $1,958,000 after buying an additional 19 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. UBS Group lifted their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $730.50.

IDEXX Laboratories Price Performance

IDXX opened at $755.96 on Thursday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a 50 day moving average of $663.01 and a two-hundred day moving average of $602.29. The company has a market cap of $60.36 billion, a P/E ratio of 62.94, a P/E/G ratio of 4.06 and a beta of 1.62. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm posted $2.80 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.98% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.